Tomáš Pika

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

Meletios Α. Dimopoulos, Philippe Moreau, Antonio Palumbo et al. · The Lancet Oncology · 2015 · 849 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

Philippe Moreau, Meletios Α. Dimopoulos, Joseph Mıkhael et al. · The Lancet · 2021 · 380 citations

Medicine, Pharmacology, Pharmacotherapy +12

Central nervous system involvement by multiple myeloma: A multi‐institutional retrospective study of 172 patients in daily clinical practice

Artur Jurczyszyn, Norbert Grząśko, Alessandro Gozzetti et al. · American Journal of Hematology · 2016 · 141 citations · Full text

Medicine, Hematology, Oncology +14

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

Philippe Moreau, D. Joshua, W-J Chng et al. · Leukemia · 2016 · 78 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

W-J Chng, Hartmut Goldschmidt, Meletios Α. Dimopoulos et al. · Leukemia · 2016 · 58 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +16